L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients

Completed · Not applicable · Has a placebo group

Conditions studied: Liver Transplant Recipients

In brief

Chronic renal insufficiency is a common and important health problem that causes morbidity and mortality among patients who have undergone liver transplantation. It is mainly caused by drugs (calcineurin inhibitors) that are used to prevent or treat rejection and once established, there is no effective treatment. This research investigates whether L-arginine can reverse the effects of calcineurin inhibitors on the kidneys and thus prevent renal insufficiency in liver transplant recipients.

Key facts

Study ID
NCT00587418
Run by
Mayo Clinic
People needed
24
Starts
2008-11-01
Expected to finish
2012-07-01
Last updated by the study team
2012-09-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.